

Open Peer Review on Qeios

## Anti-EGFRvIII/CD3 BiTE Antibody AMG 596

National Cancer Institute

## Source

National Cancer Institute. <u>Anti-EGFRvIII/CD3 BiTE Antibody AMG 596</u>. NCI Thesaurus. Code C146824.

A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one that is directed against a tumor-associated antigen (TAA), the epidermal growth factor receptor (EGFR) deletion-mutant form, EGFR variant III (EGFRVIII), and one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of anti-EGFRVIII/CD3 BiTE antibody AMG 596, the bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and EGFRVIII found on EGFRVIII-expressing tumor cells. This activates and crosslinks CTLs with EGFRVIII-expressing tumor cells, which results in the CTL-mediated cell death of EGFRVIII-expressing tumor cells. EGFRVIII, a mutation in the EGFR gene where exons 2-7 have been deleted, is overexpressed by a variety of cancers, but is absent in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and resistance to both radio- and chemotherapy.

Qeios ID: 1Q2VGL · https://doi.org/10.32388/1Q2VGL